These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8283190)

  • 1. Use of global assessment measures in dementia drug trials.
    Rockwood K
    J Clin Epidemiol; 1994 Jan; 47(1):101-3. PubMed ID: 8283190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease.
    Gauthier S; Ferris S
    Int J Clin Pract Suppl; 2001 May; (120):29-39. PubMed ID: 11406924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease.
    Knopman DS; Knapp MJ; Gracon SI; Davis CS
    Neurology; 1994 Dec; 44(12):2315-21. PubMed ID: 7991118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of global scales.
    Oremus M; Perrault A; Demers L; Wolfson C
    J Geriatr Psychiatry Neurol; 2000; 13(4):197-205. PubMed ID: 11128059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global measures: utility in defining and measuring treatment response in dementia.
    Reisberg B
    Int Psychogeriatr; 2007 Jun; 19(3):421-56. PubMed ID: 17480241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research design issues: antialuminum drug studies in Alzheimer's disease.
    Shore D; Wyatt RJ
    Clin Neuropharmacol; 1982 Dec; 5(4):337-43. PubMed ID: 7159877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global change assessments in anti-Alzheimer clinical drug trials.
    Knopman DS
    Dement Geriatr Cogn Disord; 1998; 9 Suppl 3():8-15. PubMed ID: 9853197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trials in Alzheimer's disease. A report from the Medical Research Council Alzheimer's Disease Clinical Trials Committee.
    Swash M; Brooks DN; Day NE; Frith CD; Levy R; Warlow CP
    J Neurol Neurosurg Psychiatry; 1991 Feb; 54(2):178-81. PubMed ID: 1843446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia.
    Molnar FJ; Man-Son-Hing M; Fergusson D
    J Am Geriatr Soc; 2009 Mar; 57(3):536-46. PubMed ID: 19187414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.
    Qizilbash N; Whitehead A; Higgins J; Wilcock G; Schneider L; Farlow M
    JAMA; 1998 Nov; 280(20):1777-82. PubMed ID: 9842955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of quality of life in Alzheimer's disease. Part 2: Issues in assessing drug effects.
    Salek SS; Walker MD; Bayer AJ
    Pharmacoeconomics; 1998 Dec; 14(6):613-27. PubMed ID: 10346414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials.
    Rockwood K; MacKnight C
    Neuroepidemiology; 2001 May; 20(2):51-6. PubMed ID: 11359070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome methodologies for pharmacologic trials in mild, moderate, and severe Alzheimer's disease. Proceedings of a meeting. New York, New York, July 26, 1994.
    Int Psychogeriatr; 1996; 8(2):155-344. PubMed ID: 9091069
    [No Abstract]   [Full Text] [Related]  

  • 14. Selegiline for Alzheimer's disease.
    Birks J; Flicker L
    Cochrane Database Syst Rev; 2000; (2):CD000442. PubMed ID: 10796544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-dementia Alzheimer's trials: overview.
    Aisen PS
    J Nutr Health Aging; 2010 Apr; 14(4):294. PubMed ID: 20305998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Who may benefit from disease-modifying studies in Alzheimer's disease?
    Gauthier S; Poirier J
    Alzheimers Dement; 2009 Mar; 5(2):147-8. PubMed ID: 19328447
    [No Abstract]   [Full Text] [Related]  

  • 18. Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." A proposal to increase participation in Alzheimer's disease clinical trials.
    Ryan JM; Schneider G; Jacobsen JS
    Alzheimers Dement; 2009 Mar; 5(2):140-2. PubMed ID: 19328445
    [No Abstract]   [Full Text] [Related]  

  • 19. Alzheimer's disease--clinical trials and the logic of clinical purpose.
    Karlawish J
    N Engl J Med; 2006 Oct; 355(15):1604-6. PubMed ID: 17035654
    [No Abstract]   [Full Text] [Related]  

  • 20. Scales as outcome measures for Alzheimer's disease.
    Black R; Greenberg B; Ryan JM; Posner H; Seeburger J; Amatniek J; Resnick M; Mohs R; Miller DS; Saumier D; Carrillo MC; Stern Y
    Alzheimers Dement; 2009 Jul; 5(4):324-39. PubMed ID: 19560103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.